Tallac Therapeutics

Tallac Therapeutics is a private biopharmaceutical company harnessing the power of innate and adaptive immunity to combat cancer. Tallac's pipeline of immunotherapy candidates stems from the company's novel Toll-like receptor agonist antibody conjugate (TRAAC) platform, which delivers potent Toll-like receptor (TLR9) agonists (T-CpG) to achieve targeted immune activation through systemic administration.